Nasdaq · CIK 0001725160
ZNTL Zentalis Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $2.64 on Oct 9, 2026, +106% from the 52-week low and -60% from the high.
Zentalis Pharmaceuticals, Inc. (ZNTL) has 26 SEC Form 4 filings on file from 12 insiders, the latest filed on Oct 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
9 open-market trades have been scored at ZNTL. The newest: Ingmar Bruns (Chief Medical Officer) sold $7,998 of stock on Feb 6, 2026, filed Feb 10, 2026, scored 30 (weak). The largest of the 9 shown: Matrix Capital Management Company, LP (10% owner) sold $10.0M on Dec 15, 2025, scored 57 (moderate). 3 insiders sold within 14 days of each other around Feb 6, 2026.
ZNTL closed at $2.64 on Oct 9, 2026, 106% above its 52-week low and 60% below its 52-week high.
5 Form 144 notices of planned sales are on file, the latest filed Feb 11, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Zentalis Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Ingmar Bruns Chief Medical Officer sell | $7,998 3,297 shares | -9% | +130% from low-36% from high | |
| 40Moderate | Julia Marie Eastland CEO & President sell | $21k 8,755 shares | -10% | +130% from low-36% from high | |
| 25Weak | Vincent Vultaggio PAO and PFO sell | $98k 40,224 shares | -22% | +130% from low-36% from high | |
| 10Weak | Vincent Vultaggio PAO and PFO sell | $7,875 3,096 shares | -2% | +141% from low-33% from high | |
| 50Moderate | Walters Group owner buy | $7.8M 6,459,973 shares | +92% | +30% from low-58% from high | |
| 57Moderate | Matrix Capital Management Company, LP owner sell | $10.0M 7,500,000 shares | -54% | +35% from low-57% from high | |
| 31Weak | Scott Dunseth Myers director buy | $29k 21,000 shares | +8% | +37% from low-67% from high | |
| 39Weak | Ingmar Bruns Chief Medical Officer buy | $46k 20,000 shares | +120% | - | |
| 48Moderate | Julia Marie Eastland CEO & President buy | $49k 28,500 shares | - | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 11, 2025 | Cam Gallagher Former Director, Former President & Interim CFO | 687 0.00% of outstanding | $1,374 | Feb 11, 2025 | $49k |
| Feb 3, 2025 | Cam Gallagher Former Director, Former President & Interim CFO | 28,558 0.04% of outstanding | $49k | Feb 3, 2025 | none |
| Feb 3, 2025 | Mark Lackner Chief Scientific Officer | 14,368 0.02% of outstanding | $25k | Feb 3, 2025 | $14k |
| Feb 3, 2025 | Andrea Paul Chief Legal Officer & Corporate Secretary | 13,230 0.02% of outstanding | $23k | Feb 3, 2025 | none |
| Oct 31, 2024 | Diana Hausman Former Chief Medical Officer | 9,888 0.01% of outstanding | $28k | Oct 31, 2024 | none |
Transactions
Every row filed, 33 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Ingmar Bruns Chief Medical Officer | AGrant or award Common Stock | +9,727 | $2.18 | $21k | 43,059 | 12 d ago |
| May 26, 2026 | Shannon Campbell director | AGrant or award Common Stock | +114,200 | $0.00 | $0 | 114,200 | May 27, 2026 |
| Feb 6, 2026 | Ingmar Bruns Chief Medical Officer | SOpen-market sale Common Stock | -2,962 | $2.43 | $7,197 | 33,667 | Feb 10, 2026 |
| Feb 6, 2026 | Julia Marie Eastland CEO & President | SOpen-market sale Common Stock | -7,866 | $2.43 | $19k | 80,022 | Feb 10, 2026 |
| Feb 6, 2026 | Vincent Vultaggio PAO and PFO | SOpen-market sale Common Stock10b5-1 | -29,951 | $2.43 | $73k | 156,779 | Feb 10, 2026 |
| Feb 9, 2026 | Ingmar Bruns Chief Medical Officer | SOpen-market sale Common Stock | -335 | $2.39 | $802 | 33,332 | Feb 10, 2026 |
| Feb 9, 2026 | Julia Marie Eastland CEO & President | SOpen-market sale Common Stock | -889 | $2.39 | $2,127 | 79,133 | Feb 10, 2026 |
| Feb 9, 2026 | Vincent Vultaggio PAO and PFO | SOpen-market sale Common Stock10b5-1 | -3,379 | $2.39 | $8,086 | 153,400 | Feb 10, 2026 |
| Feb 10, 2026 | Vincent Vultaggio PAO and PFO | SOpen-market sale Common Stock10b5-1 | -6,894 | $2.42 | $17k | 146,506 | Feb 10, 2026 |
| Feb 2, 2026 | Vincent Vultaggio PAO and PFO | SOpen-market sale Common Stock10b5-1 | -2,540 | $2.55 | $6,477 | 187,286 | Feb 4, 2026 |
| Feb 3, 2026 | Vincent Vultaggio PAO and PFO | SOpen-market sale Common Stock10b5-1 | -556 | $2.52 | $1,398 | 186,730 | Feb 4, 2026 |
| Jan 8, 2026 | Ingmar Bruns Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +365,000 | $0.00 | $0 | 365,000 | Jan 9, 2026 |
| Jan 8, 2026 | James B Bucher Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 9, 2026 |
| Jan 8, 2026 | Julia Marie Eastland CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +775,000 | $0.00 | $0 | 775,000 | Jan 9, 2026 |
| Jan 8, 2026 | Vincent Vultaggio PAO and PFO | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 9, 2026 |
| Dec 31, 2025 | Walters Group owner | POpen-market purchase Common Stock | +6,459,973 | $1.20 | $7.8M | 13,509,973 | Jan 8, 2026 |
| Dec 15, 2025 | Matrix Capital Management Company, LP owner | SOpen-market sale Common Stock, par value $0.001 per shareindirect: See footnotes | -7,500,000 | $1.33 | $10.0M | 6,459,973 | Dec 15, 2025 |
| Oct 1, 2025 | James B Bucher Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Oct 1, 2025 |
| Jun 17, 2025 | David Michael Johnson director | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 250,421 | Jun 18, 2025 |
| Jun 17, 2025 | Enoch Kariuki director | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 137,365 | Jun 18, 2025 |
| Jun 17, 2025 | Scott Dunseth Myers director | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 338,795 | Jun 18, 2025 |
| Jun 17, 2025 | Jan Skvarka director | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 207,154 | Jun 18, 2025 |
| Jun 17, 2025 | Luke Nathaniel Walker director | AGrant or award Common Stock | +57,603 | $0.00 | $0 | 144,284 | Jun 18, 2025 |
| Apr 30, 2025 | Scott Dunseth Myers director | POpen-market purchase Common Stock | +21,000 | $1.40 | $29k | 281,192 | Apr 30, 2025 |
| Feb 6, 2025 | Ingmar Bruns Chief Medical Officer | POpen-market purchase Common Stock | +20,000 | $2.28 | $46k | 36,629 | Feb 12, 2025 |
| Feb 3, 2025 | Ingmar Bruns Chief Medical Officer | AGrant or award Common Stock | +16,629 | $0.00 | $0 | 16,629 | Feb 5, 2025 |
| Feb 3, 2025 | Julia Marie Eastland CEO & President | AGrant or award Common Stock | +59,388 | $0.00 | $0 | 87,888 | Feb 5, 2025 |
| Feb 3, 2025 | Ingmar Bruns Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +16,629 | $0.00 | $0 | 16,629 | Feb 5, 2025 |
| Feb 3, 2025 | Julia Marie Eastland CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +59,388 | $0.00 | $0 | 59,388 | Feb 5, 2025 |
| Jan 31, 2025 | Julia Marie Eastland CEO & President | POpen-market purchase Common Stock | +28,500 | $1.73 | $49k | 28,500 | Feb 4, 2025 |
| Dec 2, 2024 | Ingmar Bruns Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +712,650 | $0.00 | $0 | 712,650 | Dec 3, 2024 |
| Dec 2, 2024 | Julia Marie Eastland CEO & President | AGrant or award Stock Option (Right to Buy)derivative | +3,028,800 | $0.00 | $0 | 3,028,800 | Dec 3, 2024 |
| Nov 13, 2024 | Scott Dunseth Myers director | AGrant or award Common Stock | +260,192 | $0.00 | $0 | 260,192 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ingmar BrunsChief Medical Officer
- James B BucherChief Legal Officer
- Shannon Campbelldirector
- Julia Marie EastlandCEO & President
- David Michael Johnsondirector
- Enoch Kariukidirector
- Matrix Capital Management Company, LPowner
- Scott Dunseth Myersdirector
- Jan Skvarkadirector
- Vincent VultaggioPAO and PFO
- Walters Groupowner
- Luke Nathaniel Walkerdirector
Questions about ZNTL
Answered from the filings on this page, as of the latest one.
Are insiders buying ZNTL?
No. In the last 90 days no insider at Zentalis Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ZNTL on the open market?
Ingmar Bruns (Chief Medical Officer) sold $7,998 of ZNTL on Feb 6, 2026 and filed the Form 4 on Feb 10, 2026. InsiderTell scored 30 (weak), with 3 insiders on the same side within 14 days.
How many insiders file Form 4 at Zentalis Pharmaceuticals, Inc.?
12 people have filed a Form 4 at Zentalis Pharmaceuticals, Inc., among them Ingmar Bruns (Chief Medical Officer), James B Bucher (Chief Legal Officer), Shannon Campbell (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.